Effect of desucumab combined with raloxifene on SHBG and SOST Levels in postmenopausal patients with osteoporosis
YAN Xiujie1, ZHUANG Wenyuan1, ZHANG Rui1, ZHANG Yue1, ZHANG Hao2
1. Department of Orthopedics, the Third Medical Center of PLA General Hospital,Beijing 100039, China; 2. Department of Orthopedic Oncology, Shanghai Long March Hospital,Shanghai 200001, China
Abstract：Objective To investigate the effects of desucumab combined with raloxifene on the levels of sex hormone binding protein (SHBG) and osteosclerosis protein (SOST) in postmenopausal osteoporosis patients. Methods A total of 140 postmenopausal osteoporosis patients admitted to the Third Medical Center of PLA General Hospital from May 2022 to May 2023 were selected and randomly divided into a control group and a study group, with 70 cases in each group. The control group was treated with raloxifene for 1 year, 60 mg/time, once/day orally, while the study group received treatment of a combination of raloxifene and desucumab for 1 year. The relevant indicators before and after treatment were collected, and the clinical effects of the two groups were compared and analyzed. Results After 1 year of treatment, the effective rate of the study group was significantly higher than that in the control group(94.29% vs. 82.86%), and the difference between the two groups was statistically significant (P<0.05).Compared with before treatment, the expression levels of estradiol (E2), follicle stimulating hormone (FSH), luteinizing hormone (LH), bone density, bone mineral content, superoxide dismutase (SOD), and glutathione (GSH) in the two groups increased after treatment, and the study group was significantly higher than the control group, with statistical significance (P<0.05). The expression levels of malondialdehyde (MDA), SHBG, SOST, type I collagen cross-linked amino terminal peptide (NTX1), type I collagen cross-linked carboxyl terminal peptide (CTX1), tartaric acid phosphatase 5b (TRACP5b), and osteocalcin (BGP) were reduced, and the study group was significantly lower than the control group, with statistical significance (P<0.05). Conclusions The combined use of desucumab and raloxifene can improve bone metabolism and oxidative stress, reduce the expression of SHBG and SOST in postmenopausal osteoporosis patients.
2024, Vol. 35 
